These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 16906356

  • 1. CSF diagnosis of Alzheimer's disease and dementia with Lewy bodies.
    Bibl M, Mollenhauer B, Esselmann H, Lewczuk P, Trenkwalder C, Brechlin P, Rüther E, Kornhuber J, Otto M, Wiltfang J.
    J Neural Transm (Vienna); 2006 Nov; 113(11):1771-8. PubMed ID: 16906356
    [Abstract] [Full Text] [Related]

  • 2. CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia.
    Bibl M, Mollenhauer B, Esselmann H, Lewczuk P, Klafki HW, Sparbier K, Smirnov A, Cepek L, Trenkwalder C, Rüther E, Kornhuber J, Otto M, Wiltfang J.
    Brain; 2006 May; 129(Pt 5):1177-87. PubMed ID: 16600985
    [Abstract] [Full Text] [Related]

  • 3. CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies.
    Mulugeta E, Londos E, Ballard C, Alves G, Zetterberg H, Blennow K, Skogseth R, Minthon L, Aarsland D.
    J Neurol Neurosurg Psychiatry; 2011 Feb; 82(2):160-4. PubMed ID: 21047883
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. CSF amyloid-β peptides in neuropathologically diagnosed dementia with Lewy bodies and Alzheimer's disease.
    Mollenhauer B, Esselmann H, Trenkwalder C, Schulz-Schaeffer W, Kretzschmar H, Otto M, Wiltfang J, Bibl M.
    J Alzheimers Dis; 2011 Feb; 24(2):383-91. PubMed ID: 21297274
    [Abstract] [Full Text] [Related]

  • 6. Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias.
    Herbert MK, Aerts MB, Kuiperij HB, Claassen JAHR, Spies PE, Esselink RAJ, Bloem BR, Verbeek MM.
    Alzheimers Dement; 2014 Jul; 10(4):448-455.e2. PubMed ID: 24239248
    [Abstract] [Full Text] [Related]

  • 7. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D, Biscetti L, Eusebi P, Salvadori N, Frattini G, Simoni S, De Roeck N, Tambasco N, Stoops E, Vanderstichele H, Engelborghs S, Mollenhauer B, Calabresi P, Parnetti L.
    Alzheimers Res Ther; 2017 Jul 28; 9(1):52. PubMed ID: 28750675
    [Abstract] [Full Text] [Related]

  • 8. Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease.
    Kasuga K, Tokutake T, Ishikawa A, Uchiyama T, Tokuda T, Onodera O, Nishizawa M, Ikeuchi T.
    J Neurol Neurosurg Psychiatry; 2010 Jun 28; 81(6):608-10. PubMed ID: 20522869
    [Abstract] [Full Text] [Related]

  • 9. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.
    Luo X, Hou L, Shi H, Zhong X, Zhang Y, Zheng D, Tan Y, Hu G, Mu N, Chan J, Chen X, Fang Y, Wu F, He H, Ning Y.
    J Neurochem; 2013 Dec 28; 127(5):681-90. PubMed ID: 23800322
    [Abstract] [Full Text] [Related]

  • 10. CSF tau, Aβ42, and MHPG differentiate dementia with Lewy bodies from Alzheimer's disease.
    Aerts MB, Esselink RA, Claassen JA, Abdo WF, Bloem BR, Verbeek MM.
    J Alzheimers Dis; 2011 Dec 28; 27(2):377-84. PubMed ID: 21841257
    [Abstract] [Full Text] [Related]

  • 11. Diagnostic markers for diagnosing dementia with Lewy bodies: CSF and MIBG cardiac scintigraphy study.
    Wada-Isoe K, Kitayama M, Nakaso K, Nakashima K.
    J Neurol Sci; 2007 Sep 15; 260(1-2):33-7. PubMed ID: 17459416
    [Abstract] [Full Text] [Related]

  • 12. Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1-42), and beta-amyloid(1-40) in cerebrospinal fluid of patients with dementia with Lewy bodies.
    Mollenhauer B, Bibl M, Wiltfang J, Steinacker P, Ciesielczyk B, Neubert K, Trenkwalder C, Otto M.
    Clin Chem Lab Med; 2006 Sep 15; 44(2):192-5. PubMed ID: 16475906
    [Abstract] [Full Text] [Related]

  • 13. The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias.
    Abu-Rumeileh S, Capellari S, Stanzani-Maserati M, Polischi B, Martinelli P, Caroppo P, Ladogana A, Parchi P.
    Alzheimers Res Ther; 2018 Jan 11; 10(1):3. PubMed ID: 29368621
    [Abstract] [Full Text] [Related]

  • 14. Homovanillic acid and 5-hydroxyindole acetic acid as biomarkers for dementia with Lewy bodies and coincident Alzheimer's disease: An autopsy-confirmed study.
    Morimoto S, Takao M, Hatsuta H, Nishina Y, Komiya T, Sengoku R, Nakano Y, Uchino A, Sumikura H, Saito Y, Kanemaru K, Murayama S.
    PLoS One; 2017 Jan 11; 12(2):e0171524. PubMed ID: 28166276
    [Abstract] [Full Text] [Related]

  • 15. Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimer's disease at the prodromal stage.
    Bousiges O, Bombois S, Schraen S, Wallon D, Quillard MM, Gabelle A, Lehmann S, Paquet C, Amar-Bouaziz E, Magnin E, Miguet-Alfonsi C, Delbeuck X, Lavaux T, Anthony P, Philippi N, Blanc F, ePLM network and collaborators.
    J Neurol Neurosurg Psychiatry; 2018 May 11; 89(5):467-475. PubMed ID: 29321140
    [Abstract] [Full Text] [Related]

  • 16. Using cerebrospinal fluid marker profiles in clinical diagnosis of dementia with Lewy bodies, Parkinson's disease, and Alzheimer's disease.
    Kaerst L, Kuhlmann A, Wedekind D, Stoeck K, Lange P, Zerr I.
    J Alzheimers Dis; 2014 May 11; 38(1):63-73. PubMed ID: 23948928
    [Abstract] [Full Text] [Related]

  • 17. Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort.
    van Steenoven I, Aarsland D, Weintraub D, Londos E, Blanc F, van der Flier WM, Teunissen CE, Mollenhauer B, Fladby T, Kramberger MG, Bonanni L, Lemstra AW, European DLB consortium.
    J Alzheimers Dis; 2016 Aug 18; 54(1):287-95. PubMed ID: 27567832
    [Abstract] [Full Text] [Related]

  • 18. Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias.
    Bibl M, Mollenhauer B, Lewczuk P, Esselmann H, Wolf S, Trenkwalder C, Otto M, Stiens G, Rüther E, Kornhuber J, Wiltfang J.
    Mol Psychiatry; 2007 Jul 18; 12(7):671-80. PubMed ID: 17339876
    [Abstract] [Full Text] [Related]

  • 19. Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies.
    Vanderstichele H, De Vreese K, Blennow K, Andreasen N, Sindic C, Ivanoiu A, Hampel H, Bürger K, Parnetti L, Lanari A, Padovani A, DiLuca M, Bläser M, Olsson AO, Pottel H, Hulstaert F, Vanmechelen E.
    Clin Chem Lab Med; 2006 Jul 18; 44(12):1472-80. PubMed ID: 17163825
    [Abstract] [Full Text] [Related]

  • 20. Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer's disease, dementia with Lewy bodies, and frontotemporal lobar degeneration.
    Ishiki A, Kamada M, Kawamura Y, Terao C, Shimoda F, Tomita N, Arai H, Furukawa K.
    J Neurochem; 2016 Jan 18; 136(2):258-61. PubMed ID: 26485083
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.